Thursday 16 October, 2025
Objectives: Ever since the semi-mechanistic model to describe drug-induced myelosuppression was published by Friberg et al. [1] (M1), several generalisations have…
Read morePoster: Drug/Disease Modelling - Oncology
Can monocyte counts predict future drug-induced neutropenia toxicities?
Thursday 16 October, 2025
Objectives: Neutropenia is a common dose-limiting toxicity in oncology patients following either chemotherapy, radiotherapy or targeted therapies. Such toxicity risks…
Read moreModeling Mouse Xenograft Tumor Growth Inhibition to Optimize Cycles in Oncology
Thursday 16 October, 2025
Introduction: Treatment of cancer requires careful consideration of the effect of the drug on the tumor while taking into account…
Read moreReduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach
Thursday 16 October, 2025
Introduction: Cancer cachexia is defined as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (sarcopenia) with…
Read moreA Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel
Thursday 16 October, 2025
Objectives: In patients receiving docetaxel or paclitaxel, patient tumor responses exhibited variable patterns of shrinkage and quiescence, followed by drug–resistant…
Read moreSelection of isatuximab dosing regimen in pediatric patients with leukemia using population PK and PBPK modeling approaches
Thursday 16 October, 2025
Introduction: Leukemia represents around 30% of cancer diagnoses among children aged less than 15 years [1][2]. Among childhood leukemias, 75%…
Read moreOptimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
Thursday 16 October, 2025
Introduction: Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) combination therapy has been shown to be an effective first line therapy for non-small cell lung cancer…
Read moreA population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor
Thursday 16 October, 2025
Objectives: CPC634 is a CriPec® nanoparticle entrapping docetaxel (DTX), conjugated via a biodegradable bond, developed to improve the tolerability and…
Read moreProjecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data
Thursday 16 October, 2025
Introduction: MIW815 (ADU-S100) is a novel immuno-oncology cyclic dinucleotide compound targeting STING (Stimulator of Interferon Genes). It is currently being…
Read moreInvestigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling
Thursday 16 October, 2025
Objectives: A lot of bispecific T-cell engaging antibodies are in preclinical and clinical development for the treatment of various types of…
Read more